Analisi di minimizzazione dei costi di bevacizumab rispetto a cetuximab nel trattamento di prima linea del carcinoma del colon-retto metastatico in Italia

    loading  Checking for direct PDF access through Ovid



Colorectal cancer (CRC) is the third most common cancer in developed countries. The incidence of CRC is generally higher for men, and the risk of the disease increases with age, as the majority of cases are diagnosed in patients more than 50 years of age. European countries rank highest in the global statistics, both in terms of incidence and mortality. The development of new chemotherapy agents and targeted therapies has increased the number of available treatment options and improved clinical outcomes for patient with metastatic colorectal cancer (mCRC). Among these new targeted therapies bevacizumab and cetuximab have been indicated for the treatment of patients with mCRC.


The present study aim was to evaluate the treatment cost of bevacizumab versus cetuximab for the first-line treatment of mCRC.


A cost-minimization analysis was performed, focusing on direct medical costs only (drugs and administration). The analysis considered the perspective of the hospital, comparing the cost of bevacizumab (5 mg/kg) versus cetuximab (400 mg/m2 and 250 mg/m2). The average cost per treated patient was assessed for the two treatment options at 6 months.


Bevacizumab is a lower-cost strategy (€12,731.17) than cetuximab (€22,904.30). This difference (€10,173.13) arises mainly from drug costs (€9,183.38) and administration costs (€989.75). The sensitivity analysis confirmed the base case results.


This analysis suggests that bevacizumab is a cost-saving alternative to cetuximab in the treatment of first-line metastatic CRC.

Related Topics

    loading  Loading Related Articles